US › Healthcare

Actuate Therapeutics, Inc. Common stock (ACTU)

US · Healthcare · Biotechnology

$1.12+5.66%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-5.6M
Profit YoY
+10.9%
EPS
$-0.24
EPS estimate
$-0.21

EPS came in at -0.24 against a street estimate of -0.21 — a miss of 14.3%.

Key statistics

Market cap
$26.6M
Forward P/E
0.0
P/B
6.99
Book value
$0.16
EPS (TTM)
$-0.98
52-week high
$9.22
52-week low
$1.03
50-day MA
$1.71
200-day MA
$4.00

Analyst view

Analysts rate Actuate Therapeutics, Inc. Common stock a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $9.98.

Shareholding

Insiders
14.84%
Institutions
58.18%

Largest institutional holders

FundStake
BIOS CAPITAL MANAGEMENT, LP42.00%
Voss Capital LLC7.21%
BlackRock Inc1.79%
Vanguard Capital Management, LLC1.67%
Geode Capital Management, LLC0.95%
Connective Capital Management LLC0.47%
Palogic Value Management LP0.42%
Northern Trust Corp0.41%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Actuate Therapeutics, Inc. Common stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.